O	0	1	5
O	1	2	-
O	2	6	year
O	7	13	follow
O	13	14	-
O	14	16	up
O	17	19	of
O	20	21	a
O	22	32	randomized
O	33	43	controlled
O	44	49	trial
O	50	52	of
O	53	62	immediate
O	63	69	versus
O	70	77	delayed
B-intervention	78	88	zoledronic
I-intervention	89	93	acid
O	94	97	for
O	98	101	the
O	102	112	prevention
O	113	115	of
B-condition	116	120	bone
I-condition	121	125	loss
O	126	128	in
O	129	143	postmenopausal
O	144	149	women
O	150	154	with
O	155	161	breast
O	162	168	cancer
O	169	177	starting
O	178	187	letrozole
O	188	193	after
O	194	203	tamoxifen
O	203	204	:
O	205	210	N03CC
O	211	212	(
O	212	220	Alliance
O	220	221	)
O	222	227	trial
O	227	228	.

O	229	243	Postmenopausal
O	244	249	women
O	250	254	with
O	255	261	breast
O	262	268	cancer
O	269	278	receiving
O	279	288	aromatase
O	289	299	inhibitors
O	300	303	are
O	304	306	at
O	307	309	an
O	310	319	increased
O	320	324	risk
O	325	327	of
O	328	332	bone
O	333	337	loss
O	337	338	.

O	339	342	The
O	343	350	current
O	351	356	study
O	357	360	was
O	361	371	undertaken
O	372	374	to
O	375	384	determine
O	385	392	whether
O	393	400	upfront
O	401	407	versus
O	408	415	delayed
O	416	425	treatment
O	426	430	with
O	431	441	zoledronic
O	442	446	acid
O	447	448	(
O	448	450	ZA
O	450	451	)
O	452	460	impacted
O	461	465	bone
O	466	470	loss
O	470	471	.

O	472	476	This
O	477	483	report
O	484	493	described
O	494	497	the
O	498	499	5
O	499	500	-
O	500	504	year
O	505	511	follow
O	511	512	-
O	512	514	up
O	515	522	results
O	522	523	.

O	524	525	A
O	526	531	total
O	532	534	of
B-total-participants	535	538	551
B-eligibility	539	553	postmenopausal
I-eligibility	554	559	women
I-eligibility	560	564	with
I-eligibility	565	571	breast
I-eligibility	572	578	cancer
I-eligibility	579	582	who
I-eligibility	583	592	completed
I-eligibility	593	602	tamoxifen
I-eligibility	603	612	treatment
I-eligibility	613	616	and
I-eligibility	617	621	were
I-eligibility	622	632	undergoing
I-eligibility	633	638	daily
I-eligibility	639	648	letrozole
I-eligibility	649	658	treatment
O	659	663	were
O	664	674	randomized
O	675	677	to
O	678	684	either
O	685	692	upfront
O	693	694	(
B-intervention-participants	694	697	274
O	698	706	patients
O	706	707	)
O	708	710	or
B-control	711	718	delayed
O	719	720	(
B-control-participants	720	723	277
O	724	732	patients
O	732	733	)
O	734	736	ZA
O	737	739	at
O	740	741	a
O	742	746	dose
O	747	749	of
O	750	751	4
O	752	754	mg
O	755	768	intravenously
O	769	774	every
O	775	776	6
O	777	783	months
O	783	784	.

O	785	787	In
O	788	791	the
O	792	800	patients
O	801	803	on
O	804	807	the
O	808	815	delayed
O	816	825	treatment
O	826	829	arm
O	829	830	,
O	831	833	ZA
O	834	837	was
O	838	847	initiated
O	848	851	for
O	852	853	a
O	854	866	postbaseline
O	867	871	bone
O	872	879	mineral
O	880	887	density
O	888	889	T
O	889	890	-
O	890	895	score
O	896	898	of
O	899	900	<
O	900	901	-
O	901	902	2
O	902	903	.
O	903	904	0
O	905	907	or
O	908	916	fracture
O	916	917	.

O	918	921	The
O	922	931	incidence
O	932	934	of
O	935	936	a
O	937	938	5
O	938	939	%
O	940	948	decrease
O	949	951	in
O	952	955	the
O	956	961	total
B-outcome	962	968	lumbar
I-outcome	969	974	spine
I-outcome	975	979	bone
I-outcome	980	987	mineral
I-outcome	988	995	density
I-outcome	996	998	at
I-outcome	999	1000	5
I-outcome	1001	1006	years
O	1007	1010	was
B-iv-bin-percent	1011	1013	10
I-iv-bin-percent	1013	1014	.
I-iv-bin-percent	1014	1015	2
I-iv-bin-percent	1015	1016	%
O	1017	1019	in
O	1020	1023	the
O	1024	1031	upfront
O	1032	1041	treatment
O	1042	1045	arm
O	1046	1052	versus
B-cv-bin-percent	1053	1055	41
I-cv-bin-percent	1055	1056	.
I-cv-bin-percent	1056	1057	2
I-cv-bin-percent	1057	1058	%
O	1059	1061	in
O	1062	1065	the
O	1066	1073	delayed
O	1074	1083	treatment
O	1084	1087	arm
O	1088	1089	(
O	1089	1090	P
O	1090	1091	<
O	1091	1092	.
O	1092	1096	0001
O	1096	1097	)
O	1097	1098	.

O	1099	1100	A
O	1101	1106	total
O	1107	1109	of
O	1110	1112	41
O	1113	1121	patients
O	1122	1124	in
O	1125	1128	the
O	1129	1136	delayed
O	1137	1146	treatment
O	1147	1150	arm
O	1151	1155	were
O	1156	1166	eventually
O	1167	1174	started
O	1175	1177	on
O	1178	1180	ZA
O	1180	1181	.

O	1182	1186	With
O	1187	1190	the
O	1191	1200	exception
O	1201	1203	of
O	1204	1213	increased
O	1214	1217	NCI
O	1218	1224	Common
O	1225	1233	Toxicity
O	1234	1242	Criteria
O	1243	1244	(
O	1244	1247	CTC
O	1247	1248	)
B-outcome	1249	1254	grade
I-outcome	1255	1256	1
I-outcome	1256	1257	/
I-outcome	1257	1258	2
I-outcome	1259	1267	elevated
I-outcome	1268	1278	creatinine
I-outcome	1279	1282	and
I-outcome	1283	1288	fever
O	1289	1291	in
O	1292	1295	the
O	1296	1304	patients
O	1305	1312	treated
O	1313	1315	on
O	1316	1319	the
O	1320	1327	upfront
O	1328	1331	arm
O	1332	1335	and
O	1336	1351	cerebrovascular
O	1352	1360	ischemia
O	1361	1366	among
O	1367	1372	those
O	1373	1375	in
O	1376	1379	the
O	1380	1387	delayed
O	1388	1397	treatment
O	1398	1401	arm
O	1401	1402	,
O	1403	1408	there
O	1409	1413	were
O	1414	1416	no
O	1417	1428	significant
O	1429	1440	differences
O	1441	1449	observed
O	1450	1457	between
O	1458	1462	arms
O	1463	1467	with
O	1468	1475	respect
O	1476	1478	to
O	1479	1482	the
O	1483	1487	most
O	1488	1494	common
O	1495	1502	adverse
O	1503	1509	events
O	1510	1512	of
B-outcome	1513	1523	arthralgia
O	1524	1527	and
B-outcome	1528	1532	back
I-outcome	1533	1537	pain
O	1537	1538	.

B-outcome	1539	1551	Osteoporosis
O	1552	1560	occurred
O	1561	1565	less
O	1566	1576	frequently
O	1577	1579	in
O	1580	1583	the
O	1584	1591	upfront
O	1592	1601	treatment
O	1602	1605	arm
O	1606	1607	(
B-iv-bin-abs	1607	1608	2
O	1609	1611	vs
B-cv-bin-abs	1612	1613	8
O	1614	1624	cumulative
O	1625	1630	cases
O	1630	1631	)
O	1631	1632	,
O	1633	1641	although
O	1642	1646	this
O	1647	1657	difference
O	1658	1661	was
O	1662	1665	not
O	1666	1671	found
O	1672	1674	to
O	1675	1677	be
O	1678	1691	statistically
O	1692	1703	significant
O	1703	1704	.

B-outcome	1705	1709	Bone
I-outcome	1710	1719	fractures
O	1720	1728	occurred
O	1729	1731	in
B-iv-bin-abs	1732	1734	24
O	1735	1743	patients
O	1744	1746	in
O	1747	1750	the
O	1751	1758	upfront
O	1759	1768	treatment
O	1769	1772	arm
O	1773	1779	versus
B-cv-bin-abs	1780	1782	25
O	1783	1791	patients
O	1792	1794	in
O	1795	1798	the
O	1799	1806	delayed
O	1807	1816	treatment
O	1817	1820	arm
O	1820	1821	.

O	1822	1831	Immediate
O	1832	1841	treatment
O	1842	1846	with
O	1847	1849	ZA
O	1850	1859	prevented
O	1860	1864	bone
O	1865	1869	loss
O	1870	1878	compared
O	1879	1883	with
O	1884	1891	delayed
O	1892	1901	treatment
O	1902	1904	in
O	1905	1919	postmenopausal
O	1920	1925	women
O	1926	1935	receiving
O	1936	1945	letrozole
O	1946	1949	and
O	1950	1955	these
O	1956	1967	differences
O	1968	1972	were
O	1973	1983	maintained
O	1984	1986	at
O	1987	1988	5
O	1989	1994	years
O	1994	1995	.

O	1996	1999	The
O	2000	2009	incidence
O	2010	2012	of
O	2013	2025	osteoporosis
O	2026	2028	or
O	2029	2038	fractures
O	2039	2042	was
O	2043	2046	not
O	2047	2052	found
O	2053	2055	to
O	2056	2058	be
O	2059	2072	significantly
O	2073	2082	different
O	2083	2090	between
O	2091	2100	treatment
O	2101	2105	arms
O	2105	2106	.
